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clinical indices of renal injury are mani-
fest, one has to look for other VEGF 
parameters. As it is possible that the 
serum level of VEGF increases before the 
renal content of VEGF decreases, this 
could allow precise timing of interven-
tion. It is important to test this hypoth-
esis in the clinical setting. Understanding 
the complex regulation of VEGF meta-
bolism in lupus patients could provide 
physicians with invaluable information 
for the treatment or prevention of lupus 
nephritis. 
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 Arachidonic acid (AA) has long been 
found to be metabolized by cyclooxy-
genase and lipoxygenase enzymes to 
prostaglandins, prostacyclin, throm-
boxane, leukotrienes, and 5-, 12-, 
and 15-hydroxyeicosatetraenoic acid 
(HETE). Recently, it was found that AA 
is also metabolized by the   -hydroxy-
lase cytochrome P450 (CYP) enzymes to 
form epoxyeicosatrienoic acids, dihy-
droxyeicosatetraenoic acids, 19-HETE, 
20-HETE, and other forms of HETE. 
The metabolites of AA generated by the 
P450 enzymes have been found to play 
important roles in the regulation of vas-
cular tone in renal, cerebral, coronary, 
and skeletal muscle arterioles and in 
pulmonary circulation. 1,2 More than 
500  CYP genes have been identified; 
among them,  CYP4F2 ,  CYP4A11 , and 
 CYP4F3B are thought to be the major 
 1 Section of Nephrology, Department of Internal 
Medicine, Yale University School of Medicine,  
 New Haven ,  Connecticut ,  USA  
 Correspondence: Yiqiang Cai, Section of 
 Nephrology, Department of Internal Medicine,
Yale University School of Medicine, 300 Cedar 
Street, New Haven, CT 6510, USA.
E-mail:  Yiqiang.cai@yale.edu 
genes involved in metabolizing AA to 
form 20-HETE. 1,2 20-HETE is a potent 
constrictor of small arteries and arteri-
oles; however, in the kidney, 20-HETE 
also regulates tubular sodium reabsorp-
tion in the proximal tubule, as well as 
in the thick ascending limb of Henle ’ s 
loop via inhibition of Na   +   -K   +   -ATPase 
activities or Na   +   -K   +   -2Cl  –  cotransport. 
Therefore, the influence of 20-HETE 
on blood pressure remains difficult to 
 predict: it could play either a prohyper-
tensive or an antihypertensive role, 
depending on its action as a vasocon-
strictor or a sodium reabsorption 
inhibitor in renal tubules. 1,3 In addi-
tion, studies in human and animal 
models also suggest diverse effects of 
 CYP gene function on blood pressure. 
In humans,  functional polymorphism 
analysis demonstrated that diverse con-
sequences resulted from genetic poly-
morphism:  the  CYP4F2  GA /  AA 
genotype was significantly associated 
with an increase in both 20-HETE 
excretion and systolic blood pressure, 
whereas the  CYP4A11 CC / TC genotype 
was significantly associated with a 
reduction in 20-HETE excretion but 
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 The cytochrome P450-derived 20-hydroxyeicosatetraenoic acid (20-HETE) 
has known function that plays opposite roles in blood pressure: 
prohypertensive and antihypertensive. Liu  et al. report that the  CYP4F2 
transgene, driven under an exogenous promoter, increases 20-HETE 
production and is associated with increased blood pressure  in vivo . 
This study provides evidence for the first time that overexpression of 
P450 4F2 enzyme results in higher production of 20-HETE, which 
promotes hypertension. The significance of this transgenic mouse model 
is further discussed. 
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was not associated with changes in 
blood pressure. 3 Furthermore, the 
 CYP4F2 M433 variant caused decreased 
production of 20-HETE. 4 On the other 
hand, the  transfer of the  CYP4A region 
of chromosome 5 from Lewis to Dahl 
salt-sensitive rats increased production 
of 20-HETE but attenuated the devel-
opment of hypertension and renal dis-
ease. 5 These data combined indicate 
that further investigation is needed to 
better understand the overall effect of 
the functioning of  CYP genes and 20-
HETE on blood pressure  in vivo . 
 Liu and colleagues 6 (this issue) estab-
lished a novel transgenic mouse model 
in which the human  CYP4F2 gene was 
overexpressed under regulation of the 
mouse kidney androgen-regulated pro-
tein promoter. The authors showed 
overexpression of the  CYP4F2 trans-
gene in proximal tubules of the kidney 
but also in other organs. They found 
increased   -hydroxylase activities and 
renal 20-HETE production in trans-
genic mice. Of importance, among 
three transgenic mouse lines, two were 
found to have significantly elevated 
systolic blood pressure that was posi-
t ively associated with increased 
 CYP4F2 expression and 20-HETE pro-
duction. This study provides a novel 
gain-of-function mouse model show-
ing for the first time that increased 
expression of the wild-type  CYP4F2 
gene results in increased production of 
20-HETE and a positive association 
with elevated blood pressure  in vivo . 
Considering the many potential effects 
that 20-HETE may have on blood pres-
sure, the study by Liu  et al. 6 suggests 
that increased production of 20-HETE 
has a prohypertensive role  in vivo . In 
addition, previous studies showed that 
functional polymorphism of  CYP4F2 
could result in either increased or 
decreased 20-HETE product ion 
depending on the type of variation. 3,4 
The study by Liu  et al. 6 suggests that 
the change in 20-HETE production, 
which links to a  CYP4F2 polymor-
phism, may result from changes in the 
activity of the P450 4F2 enzyme. Cur-
rently, the mechanism or mechanisms 
that link  CYP4F2 -derived increased 
20-HETE production and elevated 
blood pressure remain unclear in this 
transgenic model ( Figure 1 ). 
 It was reported for the first time by 
Ward  et al. that urinary 20-HETE is 
associated with endothelial dysfunction 
in humans. 7 Moreover, an experimental 
study in rats further revealed that vas-
cular P450 4A expression and 20-HETE 
synthesis contribute to endothelial 
 dysfunction in androgen-induced 
 hypertension. 8 Whether endothelial 
dysfunction resulted from the P450 
4F2-derived increased 20-HETE pro-
duction in the mouse model of Liu  et 
al. 6 remains undetermined. It is note-
worthy that one transgenic mouse line 
in their study, F0-6, has slightly higher 
urinary 20-HETE than the transgenic 
line F0-56, which has elevated blood 
pressure but lacks significant elevated 
blood pressure in male mice. Whether 
this phenomenon results from genetic 
variation or reflects involvement of 
other factors such as endothelial dys-
function in the hypertensive phenotype 
remains to be determined. Another 
possibility is that increased  CYP4F2 
gene expression may also result in 
increased production of 19-HETE, 
another metabolite of AA, which may 
act as a competitive antagonist of the 
inhibitory effects of 20-HETE on 
sodium reabsorption in the  kidney. 
Further studies to address the above 
possibilities would help in understand-
ing the mechanism(s) that l inks 
increased expression of  CYP4F2 and 
20-HETE production to elevated blood 
pressure in this transgenic model. 
 Finally, transgene expression driven by 
the exogenous promoter might not 
 faithfully recapitulate the native distribu-
tion pro. le of the target gene, which may 
result in functional consequences not seen 
in wild-type circumstances. In this regard, 
transgenic mouse overexpression of a 
 bacterial artificial chromosome (BAC)-
 CYP4F2 gene that carries the endogenous 
promoter may serve as a faithful model to 
establish the link between P450 4F2-derived 
20-HETE  production and changes in 
blood pressure  in vivo . 
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 Figure 1  |  Model of CPY4F2 gene function. 
Increased expression of CYP4F2 that caused 
increased production of 20-HETE was 
associated with elevated blood pressure. 
However, the mechanism(s) underlying 
the link between increased 20-HETE and 
hypertension, and whether other factors 
contributed to the elevated blood pressure, 
remain unknown. 
